Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus

Diabetology & Metabolic Syndrome

Research

Yuan Lin¹  Tzu-Hsien Tsai²  Ming-Shyan Lin³  Tien-Hsing Chen⁴  Ning-I Yang⁴  Ming-Jui Hung⁴  Chao-Yung Wang⁵  I-Chang Hsieh⁵  Ming-Lung Tsai⁶ 

[1]Department of Emergency Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan

[2]Chang Gung University College of Medicine, Taoyuan, Taiwan

[3]Division of Cardiology and Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan

[4]Division of Cardiology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan

[5]Chang Gung University College of Medicine, Taoyuan, Taiwan

[6]Division of Cardiology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan

[7]Chang Gung University College of Medicine, Taoyuan, Taiwan

[8]Division of Cardiology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

[9]Chang Gung University College of Medicine, Taoyuan, Taiwan

[10]Division of Cardiology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan

[11]Chang Gung University College of Medicine, Taoyuan, Taiwan

关键词: ARNI;    SGLT2i;    Heart failure;    Renal function;    Diabetes mellitus;   

DOI  :  10.1186/s13098-023-01081-2

 received in 2023-03-12, accepted in 2023-05-08,  发布年份 2023

来源: Springer

【 摘 要 】

Background and aimsClinical comparisons of angiotensin receptor–neprilysin inhibitors (ARNI) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) treatment in patients with HFrEF and T2DM are limited. This study evaluated the clinical outcomes and treatment benefits of SGLT2i versus ARNI treatment in patients with HFrEF and T2DM in a large real-world data set.MethodsWe identified 1487 patients with HFrEF and T2DM who were undergoing ARNI or SGLT2i treatment for the first time (n = 647 and 840, respectively) between January 1, 2016, and December 31, 2021, and with clinical outcomes of CV death, hospitalization for heart failure (HHF), composite CV outcomes, or renal outcomes.ResultsThe HHF risk reduction conferred by SGLT2i treatment was more significant than that conferred by ARNI treatment (37.7% vs. 30.4%; 95% confidence interval [CI] 1.06–1.41). SGLT2i use conferred significantly greater renal protection against the doubling of serum creatinine (13.1% vs. 9.3%; 95% CI 1.05–1.75), an estimated glomerular filtration rate decline of > 50% (24.9% vs. 20.0%; 95% CI 1.02–1.45), and progression to end-stage renal disease (3.1% vs. 1.5%; 95% CI 1.62–5.23). The improvements in echocardiographic parameters were comparable between the groups.ConclusionsCompared with ARNI treatment, SGLT2i treatment was associated with a more significant HHF risk reduction and greater preservation of renal function in patients with HFrEF and T2DM. This study also supports the prioritization of SGLT2i use in these patients when patients' conditions or economic resources need to be considered.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

40517_2023_256_Article_IEq128.gif

40517_2023_256_Article_IEq109.gif

Fig. 4

Fig. 2

Fig. 2

Fig. 2